Pluvicto News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pluvicto. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pluvicto Today - Breaking & Trending Today
i know i could find a gas station anywhere, but e.v., what if i m low on electric juice. i would consider anything that s electric and that performance well. the fact is that the battery is reduced by 40% in cold, cold weather. we placed the order, we are getting a tesla. i would rather work on it myself rather than somebody else do it. the biden administration, strict now limits on gas powered vehicles killing cars as we know them today, and arguably ending an era that helped turn america into a global superpower. hello, welcome everyone, sandra smith in new york. bill: i m bill melugin in for john roberts. aggressive proposal by the e.p.a., transforming the auto industry. sandra: requiring as many as two-thirds of new cars and trucks in this country sold by 2032 to be electric. critics of this plan say president biden s sweeping climate agenda is moving unreasonably fast and is an attempt to kill the combustion engine, which revolutionized industrial m ....
Novartis AG shares slumped after the drugmaker reported earnings that came short of analysts’ estimates on weak revenue from Pluvicto, a prostate cancer treatment that faced supply constraints. ....
Novartis AG’s radioligand therapy, Pluvicto, a bestseller for the company that has been restructuring itself, continues to show strong growth in the third quarter of 2023, according to its most recent financial results. Sales were up 217% from the same quarter in 2022 at $256 million. Analysts are predicting blockbuster sales. ....
Treatment with lutetium Lu 177 vipivotide tetraxetran improved radiographic progression-free survival compared with abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer who were taxane naïve and experienced disease progression on a prior second-generation androgen receptor pathway inhibitor. ....